RxDoctor Payments Data

Olga German, MD

Ophthalmology · Geneva, ILNPI 1346635331

Payments from drug & device makers

$4,399in general payments, 2019–2025

Across 69 payments — averaging $63.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$956
  • Alcon$882
  • Regeneron Healthcare Solutions, Inc.$543
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$543
  • Apellis Pharmaceuticals, Inc.$346
  • Genentech USA, Inc.$257
  • plus $871 from 9 others

What the payments were for

  • Consulting fees$75017%
  • Food & beverage$3,64983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,399 in reported general payments places this provider in the 75th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,672,602
Medicare patients
837
Services billed
19,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$20,418
XiidraLifitegrast11$17,422
LumiganBimatoprost32$15,885
ProlensaBromfenac Sodium17$6,294
Cyclosporine13$6,288
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$6,006
Difluprednate27$3,937
Brimonidine Tartrate17$3,254
Travoprost14$3,209
SimbrinzaBrinzolamide/Brimonidine Tart14$2,882
Brinzolamide11$2,076
Latanoprost130$2,016
Prednisolone Acetate58$1,900
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$1,191
Timolol Maleate50$1,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$956$36,30253 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$543$6,29417 claims
AlconSimbrinza$882$2,88214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Geneva

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →